Streetbeat News

Partnerships

DTIL

LLY

Precision BioSciences, Inc. has amended and restated its development and license agreement with Prevail Therapeutics Inc., a subsidiary of Eli Lilly and Company, to collaborate on developing potential in vivo therapies for genetic disorders.

Portfolio Pulse from Happy Mohamed

July 06, 2023 | 12:07 pm

CRBU

PFE

Caribou Biosciences has announced a $25 million equity investment from Pfizer. This investment could potentially strengthen the financial position of Caribou Biosciences and foster a strategic partnership with Pfizer.

Portfolio Pulse from Benzinga Newsdesk

July 06, 2023 | 12:06 pm

RDHL

Phil Inc. has partnered with RedHill Biopharma (NASDAQ:RDHL) to make RedHill's medication Talicia® available via the PhilRx Patient Access Platform. The platform simplifies the prescription process, including insurance coverage and reimbursement. The partnership aims to increase patient access to Talicia®, a treatment for Helicobacter pylori infection.

Portfolio Pulse from Happy Mohamed

July 06, 2023 | 12:05 pm

EGIO

Edgio, Inc. (NASDAQ:EGIO) has announced a reseller partnership with Vermantia, a global provider of omni-channel content solutions for gaming and betting operators. The collaboration will support Vermantia's custom-built, end-to-end streaming solutions for live racing, sports events, virtual sports, and number games.

Portfolio Pulse from Benzinga Newsdesk

July 06, 2023 | 12:02 pm

PXMD

PaxMedica, Inc. (NASDAQ:PXMD) has signed an exclusive pharmacy distribution agreement with Vox Nova LLC for its lead pipeline asset, PAX-101. PaxMedica is a biopharmaceutical company focused on developing novel anti-purinergic drug therapies for Autism Spectrum Disorder (ASD) and other neurological conditions.

Portfolio Pulse from Benzinga Newsdesk

July 06, 2023 | 12:01 pm

STSS

Sharps Technology, Inc. (NASDAQ: STSS and STSSW), a medical device and drug delivery company, has been featured in Med Tech Outlook as the 'Top Safety Syringe Manufacturer in 2023'. The company is advancing its products from research and development to commercial sales, expected to launch in 2023. The article also highlights Sharps' partnership with Nephron Pharmaceuticals and its next-generation polymer-based prefillable syringe systems.

Portfolio Pulse from Benzinga Newsdesk

July 06, 2023 | 11:53 am

BABA

MSFT

NVDA

Alibaba Group Holding Limited (NYSE:BABA) is partnering with Zhejiang province to develop artificial intelligence and the digital economy. The collaboration aims to create a better business environment for platform-economy firms and encourage innovations in AI. Alibaba is integrating its large language model across its business lines to improve user experience. Nvidia Corp (NASDAQ:NVDA) and Microsoft Corp (NASDAQ:MSFT) highlighted the benefits of generative AI during an Alibaba summit in June.

Portfolio Pulse from Anusuya Lahiri

July 06, 2023 | 11:52 am

EADSY

RTX

Airbus SE has signed a memorandum of understanding with Mexican airline Viva Aerobus for 90 A321neo aircraft. The planes will be powered by Pratt & Whitney GTF engines, a unit of Raytheon Technologies Corporation. The order is expected to be delivered by 2027. The financial terms were not disclosed.

Portfolio Pulse from Nabaparna Bhattacharya

July 06, 2023 | 11:41 am

VBIV

VBI Vaccines Inc has expanded its hepatitis B partnership with Brii Biosciences. Brii Bio has acquired a worldwide exclusive license for VBI-2601 and an exclusive license for PreHevbri in the Asia Pacific region from VBI. Brii Bio will pay VBI an upfront payment of $15 million, including an equity investment of approximately $3 million, contingent on achieving near-term milestones. VBI is also eligible to receive up to an additional $422 million in potential regulatory and commercial milestone payments and double-digit royalties in the licensed territories worldwide for VBI-2601 and APAC, excluding Japan, for PreHevbri. VBIV shares are down 28.50% at $1.73 during the premarket session on the last check Thursday.

Portfolio Pulse from Vandana Singh

July 06, 2023 | 11:38 am

GENI

Genius Sports Ltd (NYSE:GENI) has extended its strategic deal with The National Football League (NFL) to remain the exclusive distributor of NFL's official live game data and Next Gen Stats feeds to global media and betting markets until the end of the 2027-28 season. The deal also includes the right to distribute NFL Watch & Bet low latency live game video feeds to sportsbooks internationally. GENI's shares are trading higher by 12.7% at $6.55 premarket.

Portfolio Pulse from Lekha Gupta

July 06, 2023 | 11:25 am